share_log

双鹭药业(002038.SZ):吉卡宾尚处于三期临床研究阶段

Shuanglu Pharmaceutical (002038.SZ): Gicabine is still in phase III clinical research

Gelonghui Finance ·  Dec 1, 2023 04:26

Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Please tell me about the development progress of your gigacabine and febusil in China?” The company replied that gigabine is still in phase III clinical research, febusta has been conditionally listed in the US, and that the domestic listing application is under normal review.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment